Our recent study on four types of GBM cells expressing low (U251-MG and T98-MG) and high (CRT-MG and U87-MG) levels of superoxide dismutase (SOD) suggested that astaxanthin sensitizes low-SOD2-expressing GBM cells to TRAIL treatment by pathways involving mitochondrial potential-mediated apoptosis that SOD2 can inhibit. Here, SOD2 is linked to glioblastoma.